Cancer Supportive Care Drugs Market Size, Share, Industry Trends and Forecast to 2030

Cancer Supportive Care Drugs Market Size & CAGR in 2021

The global cancer supportive care drugs market is anticipated to experience a Compound Annual Growth Rate (CAGR) of 4.5% from 2021 to 2026. As a result, the market is projected to reach a value of USD 26.1 billion by the end of 2021.

COVID-19 Impact on the Cancer Supportive Care Drugs Market

The COVID-19 pandemic has had a significant impact on the cancer supportive care drugs market. Due to the global health crisis, there has been a disruption in the supply chain of pharmaceutical products, leading to a shortage of essential cancer supportive care drugs. Additionally, the focus of healthcare systems on addressing the pandemic has resulted in a decrease in cancer screenings and treatments, affecting the demand for supportive care drugs.

Cancer Supportive Care Drugs Dynamics

The cancer supportive care drugs market is driven by factors such as the increasing prevalence of cancer worldwide, the growing demand for personalized cancer treatments, and advancements in supportive care therapies. Additionally, the rise in the aging population and the expansion of healthcare infrastructure in developing countries contribute to the market's growth.

Segments and Related Analysis

By Drug Type:

- Chemotherapy-Induced Nausea and Vomiting (CINV) Drugs

- Anemia Management Drugs

- Bone Metabolism Regulators

- Others

By Cancer Type:

- Breast Cancer

- Lung Cancer

- Prostate Cancer

- Colorectal Cancer

- Others

By Region Analysis

North America:

- The North American market for cancer supportive care drugs is expected to lead globally due to factors such as advanced healthcare infrastructure, high prevalence of cancer, and increasing investments in research and development.

Europe:

- The European market is anticipated to witness significant growth in the coming years, driven by increasing awareness about cancer care, favorable government initiatives, and the presence of key market players in the region.

Asia Pacific:

- The Asia Pacific region is projected to experience rapid growth in the cancer supportive care drugs market due to the increasing incidence of cancer, improving healthcare infrastructure, and rising disposable income levels.

Key Market Players and Competitive Landscape

Some of the key players in the cancer supportive care drugs market include Pfizer Inc., Amgen Inc., F. Hoffmann-La Roche Ltd, Novartis AG, and Merck & Co., Inc. These companies are focusing on strategic collaborations, product launches, and acquisitions to strengthen their market presence.

Recent Happenings in the Cancer Supportive Care Drugs Market

- In February 2021, Pfizer Inc. received approval from the FDA for a new cancer supportive care drug to manage chemotherapy-induced nausea and vomiting.

- In September 2021, Amgen Inc. announced a partnership with a leading research institution to develop personalized cancer supportive care therapies.

- In November 2021, Novartis AG launched a new bone metabolism regulator for the treatment of cancer-related bone complications.